Related Experiment Video
Updated: Jul 20, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Successful percutaneous coronary intervention using bivalirudin in a patient with chronic lymphocytic leukemia and
1The Heart and Vascular Institute of Florida, Clearwater, FL 33756, USA. mkrolick@tampabay.rr.com
Insights
This case study highlights the safe use of bivalirudin, a direct thrombin inhibitor, for anticoagulation during percutaneous coronary intervention (PCI) in a patient with chronic lymphocytic leukemia and thrombocytopenia. Bivalirudin effectively managed anticoagulation without complications in this high-risk patient.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Patients with chronic lymphocytic leukemia (CLL) and thrombocytopenia face elevated risks during invasive cardiac procedures like percutaneous coronary intervention (PCI).
- Optimal anticoagulation choice is critical to mitigate both ischemic and bleeding complications in these high-risk individuals.
Observation:
- A case report details a patient diagnosed with chronic lymphocytic leukemia and concurrent thrombocytopenia.
Findings:
- The patient underwent percutaneous coronary intervention (PCI) with stenting for cardiac conditions.
- Anticoagulation during the procedure was successfully managed using bivalirudin, a direct thrombin inhibitor.
- The patient experienced no procedural complications and tolerated the intervention well.
Implications:
- This case suggests bivalirudin is a potentially safe and effective anticoagulation option for patients with increased bleeding risk undergoing PCI.
- Further research may explore bivalirudin's role in managing anticoagulation for complex cardiac interventions in patients with hematological malignancies.
Abstract:
A patient with chronic lymphocytic leukemia and thrombocytopenia who underwent percutaneous coronary intervention (PCI) and stenting is presented. Patients with these concomitant diseases who require invasive cardiac procedures are at increased risk for ischemic and bleeding complications and the choice of anticoagulation in these patients is critical. In the present case, anticoagulation was achieved with the direct thrombin inhibitor bivalirudin. No complications were reported, and the patient tolerated the procedure well. This case suggests that bivalirudin may be safely used in patients who are at an increased risk of bleeding undergoing PCI.
